Ponatinib reduces viability, migration, and functionality of human endothelial cells-Reference-Cited by-同舟云学术

Ponatinib reduces viability, migration, and functionality of human endothelial cells

Published:2016-10-12 Issue:6 Volume:58 Page:1455-1467
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gover-Proaktor Ayala¹,Granot Galit¹,Shapira Saar¹²,Raz Oshrat¹,Pasvolsky Oren²³,Nagler Arnon²⁴,Lev Dorit L.¹,Inbal Aida³,Lubin Ido¹²,Raanani Pia²³,Leader Avi²³

Affiliation:

1. Felsenstein Medical Research Center, Tel Aviv, Israel;

2. The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;

3. Division of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel;

4. Division of Hematology, Chaim Sheba Medical Center, Tel Aviv, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1239258

Reference49 articles.

1. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

2. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia

3. Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?

4. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

5. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase;Archives of Biochemistry and Biophysics;2024-08

2. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

3. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling;Molecular and Cellular Biochemistry;2024-07-15

4. Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia;British Journal of Haematology;2024-06-15

5. Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis;Pharmaceutics;2024-04-19